Position in ALNY
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$539,445
+$25,604 QoQ
Shares Held
1,792
+15.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#471
of 780 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NORDEN GROUP LLC holds $6,505,916 across 12 Biotechnology names. ALNY ranks #5 (8.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,542 | $1,759,417 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,645 | $1,025,723 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
9,260 | $724,780 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
1,783 | $563,588 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
1,792 | $539,445 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
7,461 | $409,907 | |
| 7 | PTGX |
Protagonist Therapeutics, Inc
|
2,868 | $351,559 | |
| 8 | TECH |
BIO-TECHNE Corp
|
3,884 | $274,404 |
All Filings in ALNY
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $539,445 | 1,792 | Shares | Sole | 2026-07-29 | |
| 2026-03-31 | $513,841 | 1,553 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $473,203 | 1,190 | Shares | Sole | 2026-01-13 | |
| 2025-09-30 | $643,416 | 1,411 | Shares | Sole | 2025-10-15 | |
| No filing history on record for this holder in this stock. | ||||||